Clinical Trial Update: Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis [Phase 3]

View source ↗

Summary

Phase 3 results comparing cefepime/nacubactam or aztreonam/nacubactam against imipenem/cilastatin for complicated urinary tract infection and acute pyelonephrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Urinary Tract Infection
• Pyelonephritis

Drugs mentioned

• Aztreonam/Nacubactam (aztreonam/nacubactam)
• Cefepime/Nacubactam (cefepime/nacubactam)
• Imipenem/Cilastatin (imipenem/cilastatin)

Snippet

Sponsor: Meiji Seika Pharma Co., Ltd. | Conditions: Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Status: COMPLETED | Results posted: 2025-11-25